Cabaletta Bio (CABA) Net Income towards Common Stockholders (2018 - 2025)

Cabaletta Bio's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$37.0 million for Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 13.55% year-over-year to -$37.0 million in Q4 2025; TTM through Dec 2025 was -$194.1 million, a 9.4% increase from a year earlier, with the FY2025 full-year figure at -$324.1 million, down 43.49% from the prior year.
• Net Income towards Common Stockholders rose to -$37.0 million in Q4 2025 per CABA's latest filing, from -$66.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$13.9 million in Q4 2021 and bottomed at -$94.8 million in Q1 2024.
• The 5-year median for Net Income towards Common Stockholders is -$33.3 million (2023), against an average of -$38.1 million.
• Across the five-year window, Net Income towards Common Stockholders slumped 327.09% in 2023 and soared 56.62% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$13.9 million in 2021, then sank by 33.92% to -$18.6 million in 2022, then dropped by 11.15% to -$20.7 million in 2023, then tumbled by 57.6% to -$32.6 million in 2024, then fell by 13.55% to -$37.0 million in 2025.
• Per Business Quant, the three latest CABA Net Income towards Common Stockholders figures stand at -$37.0 million (Q4 2025), -$66.9 million (Q3 2025), and -$49.1 million (Q2 2025).